ERBB3 and lung carcinoma: According to a recent study, AXL is stimulated by osimertinib after the termination of a negative feedback loop into SPRY4 in EGFR‐mutant lung cancer cells, resulting in the expression of HER3 and EGFR to maintain cell survival and promote osimertinib tolerance.220